Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma

被引:75
作者
Leitao, MM
Brennan, MF
Hensley, M
Sonoda, Y
Hummer, A
Haskaran, D
Venkatraman, E
Alektiar, K
Barakat, RR
机构
[1] Mem Sloan Kettering Canc Ctr, Gynecol Serv, Acad Off, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Gastr & Mixed Tumor Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Dev Chemotherapy Serv, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Gynecol Dis Management Team, New York, NY 10021 USA
关键词
D O I
10.1006/gyno.2002.6840
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The objective was to determine long-term survival and predictors of outcome in a retrospective cohort of patients who underwent surgical resection of recurrent uterine leiomyosarcoma (LMS). Methods. Between January 1991 and March 2001, 41 patients who underwent surgical resection for recurrent uterine leiomyosarcoma were identified. The records of these patients were reviewed and abstracted data included patient age, date of initial diagnosis, tumor histology and grade, residual tumor after all operations, the use of adjuvant therapy, dates and sites of all recurrences, and disease status at last follow-up. Survival was determined from the time of first recurrence to last follow-up. Survival curves were estimated using the Kaplan-Meier method and P values were generated using the likelihood ratio test from the Cox proportional hazards model and X-2 analysis. Results. Forty-one patients with recurrent uterine LMS (17 local pelvic, 18 distant, 6 both) underwent surgical resection at time of first recurrence. A thoracic procedure alone was performed in 13 cases. Information on residual disease was available for 37 patients. The disease-specific 2-year survival for all 41 patients was 71.2% (95% Cl: 58.1, 87.3). In univariate analysis, time to first recurrence and optimal resection were significantly associated with longer overall survival. Conclusion. Optimal surgical resection for recurrent uterine leiomyosarcoma may provide an opportunity for long-term survival in a select patient population. Time to first recurrence and optimal surgical resection were predictors of improved outcome in this study. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:287 / 294
页数:8
相关论文
共 37 条
[11]   Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial [J].
Hensley, ML ;
Maki, R ;
Venkatraman, E ;
Geller, G ;
Lovegren, M ;
Aghajanian, C ;
Sabbatini, P ;
Tong, W ;
Barakat, R ;
Spriggs, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2824-2831
[12]   OBSERVATIONS ON THE USE OF ADJUVANT RADIATION-THERAPY IN PATIENTS WITH STAGE-I AND STAGE-II UTERINE SARCOMA [J].
HORNBACK, NB ;
OMURA, G ;
MAJOR, FJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1986, 12 (12) :2127-2130
[13]   THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA [J].
HOSKINS, WJ ;
MCGUIRE, WP ;
BRADY, MF ;
HOMESLEY, HD ;
CREASMAN, WT ;
BERMAN, M ;
BALL, H ;
BEREK, JS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (04) :974-980
[14]  
HOSKINS WJ, 1999, CANC RES THER CONTR, V9, P373
[15]   RESECTION OF PULMONARY METASTASES FROM UTERINE SARCOMAS [J].
LEVENBACK, C ;
RUBIN, SC ;
MCCORMACK, PM ;
HOSKINS, WJ ;
ATKINSON, EN ;
LEWIS, JL .
GYNECOLOGIC ONCOLOGY, 1992, 45 (02) :202-205
[16]   Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases [J].
Mayerhofer, K ;
Obermair, A ;
Windbichler, G ;
Petru, E ;
Kaider, A ;
Hefler, L ;
Czerwenka, K ;
Leodolter, S ;
Kainz, C .
GYNECOLOGIC ONCOLOGY, 1999, 74 (02) :196-201
[17]  
Mazumdar M, 2000, STAT MED, V19, P113, DOI 10.1002/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.0.CO
[18]  
2-O
[19]   CHANGING-ROLE OF SURGERY FOR PULMONARY METASTASES [J].
MCCORMACK, PM ;
MARTINI, N .
ANNALS OF THORACIC SURGERY, 1979, 28 (02) :139-145
[20]   Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas - A Gynecologic Oncology Group study [J].
Miller, DS ;
Blessing, JA ;
Kilgore, LC ;
Mannel, R ;
Van Le, L .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04) :355-357